

Joop A M J L Janssen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875773/publications.pdf>

Version: 2024-02-01

143
papers

8,211
citations

43973

48
h-index

51492

86
g-index

151
all docs

151
docs citations

151
times ranked

8469
citing authors

#	ARTICLE	IF	CITATIONS
1	It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S1-S12.	1.8	17
2	Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. <i>Cells</i> , 2021, 10, 383.	1.8	10
3	Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells. <i>Frontiers in Oncology</i> , 2021, 11, 645732.	1.3	2
4	Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7797.	1.8	88
5	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4626-e4637.	1.8	2
6	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1397-e1407.	1.8	3
7	Mechanisms of putative IGF-I receptor resistance in active acromegaly. <i>Growth Hormone and IGF Research</i> , 2020, 52, 101319.	0.5	8
8	Soluble Klotho: a possible predictor of quality of life in acromegaly patients. <i>Endocrine</i> , 2020, 69, 165-174.	1.1	10
9	New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations. <i>Cells</i> , 2020, 9, 862.	1.8	24
10	The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease. <i>Growth Hormone and IGF Research</i> , 2019, 48-49, 16-28.	0.5	8
11	IGF-I and the endocrinology of aging. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 5, 1-6.	0.6	5
12	Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. <i>Endocrine Reviews</i> , 2019, 40, 236-267.	8.9	117
13	How to Position Pasireotide LAR Treatment in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1978-1988.	1.8	32
14	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	1.1	23
15	Revisiting the Role of Insulin-Like Growth Factor-I Receptor Stimulating Activity and the Apolipoprotein E in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 20.	1.7	24
16	Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 915-924.	1.8	37
17	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. <i>European Journal of Endocrinology</i> , 2019, 181, 173-183.	1.9	12
18	Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 586-595.	1.8	58

#	ARTICLE	IF	CITATIONS
19	Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins. <i>European Journal of Endocrinology</i> , 2018, 178, 153-161.	1.9	3
20	Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms. <i>Transplantation Direct</i> , 2018, 4, e350.	0.8	8
21	Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. <i>European Journal of Endocrinology</i> , 2018, 178, 93-102.	1.9	42
22	Disagreement in normative IGF levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency. <i>Clinical Endocrinology</i> , 2018, 88, 409-414.	1.2	8
23	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. <i>European Journal of Endocrinology</i> , 2018, 178, 11-22.	1.9	41
24	Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. <i>European Journal of Endocrinology</i> , 2018, 179, 269-277.	1.9	38
25	Very long-term sequelae of craniopharyngioma. <i>European Journal of Endocrinology</i> , 2017, 176, 755-767.	1.9	76
26	Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3814-3821.	1.8	3
27	Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747). <i>Thyroid</i> , 2017, 27, 1458-1459.	2.4	10
28	Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. <i>Neuroendocrinology</i> , 2017, 105, 44-53.	1.2	24
29	Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up. <i>International Journal of Obesity</i> , 2017, 41, 210-216.	1.6	45
30	Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2016, 103, 815-825.	1.2	11
31	Genomewide meta-analysis identifies loci associated with IGF and IGFBP levels with impact on age-related traits. <i>Aging Cell</i> , 2016, 15, 811-824.	3.0	83
32	Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2016, 23, 727-737.	1.6	21
33	Impact of Physical Exercise on Endocrine Aging. <i>Frontiers of Hormone Research</i> , 2016, 47, 68-81.	1.0	30
34	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.4	117
35	What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?. <i>European Journal of Endocrinology</i> , 2016, 174, 663-667.	1.9	11
36	Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2016, 7, 167.	1.5	31

#	ARTICLE	IF	CITATIONS
37	Potency of Full- Length MGF to Induce Maximal Activation of the IGF-1 R Is Similar to Recombinant Human IGF-1 at High Equimolar Concentrations. PLoS ONE, 2016, 11, e0150453.	1.1	6
38	Absence or low IGF-1R expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. Journal of Surgical Oncology, 2015, 111, 1047-1053.	0.8	5
39	An Early Diagnostic Tool for Diabetic Peripheral Neuropathy in Rats. PLoS ONE, 2015, 10, e0126892.	1.1	13
40	The Introduction of the IDS-iSYS Total IGF-1 Assay May Have Far-Reaching Consequences for Diagnosis and Treatment of GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 309-316.	1.8	19
41	Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults. European Journal of Endocrinology, 2015, 173, 119-127.	1.9	3
42	IFN- γ is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. American Journal of Cancer Research, 2015, 5, 2035-46.	1.4	3
43	Diabetes Associated with Glucocorticoid Excess. Frontiers in Diabetes, 2014, , 22-33.	0.4	1
44	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	1.6	25
45	Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3644-3652.	1.8	103
46	IGF-IR Targeted Therapy: Past, Present and Future. Frontiers in Endocrinology, 2014, 5, 224.	1.5	49
47	Insulin Analogs and Cancer: A Note of Caution. Frontiers in Endocrinology, 2014, 5, 79.	1.5	14
48	Insulin-Like Growth Factor-1 Receptor Stimulating Activity is Associated with Dementia. Journal of Alzheimer's Disease, 2014, 42, 137-142.	1.2	25
49	In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocrine Connections, 2014, 3, 85-92.	0.8	12
50	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4942-4952.	1.8	81
51	Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-1, and Human Insulin on Insulin and IGF-1 Receptor Signaling. Diabetes, 2013, 62, 2539-2544.	0.3	19
52	Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling. Molecular and Cellular Endocrinology, 2013, 365, 17-24.	1.6	9
53	IGF-1 Bioactivity Might Reflect Different Aspects of Quality of Life Than Total IGF-1 in GH-Deficient Patients During GH Treatment. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 761-768.	1.8	23
54	Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. Endocrine Connections, 2013, 2, 172-177.	0.8	11

#	ARTICLE	IF	CITATIONS
55	Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients With Graves' Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 769-776.	1.8	161
56	High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control. <i>Diabetes Care</i> , 2013, 36, 1619-1628.	4.3	309
57	Insulin and its analogues and their affinities for the IGF1 receptor. <i>Endocrine-Related Cancer</i> , 2012, 19, F63-F75.	1.6	83
58	High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. <i>European Journal of Endocrinology</i> , 2012, 167, 111-117.	1.9	25
59	Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. <i>Diabetologia</i> , 2012, 55, 1186-1194.	2.9	14
60	Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians' offspring. <i>Aging</i> , 2012, 4, 580-589.	1.4	78
61	Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 372-7.	1.8	1
62	Effect of Intensive Insulin Therapy on the Somatotrophic Axis of Critically Ill Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2558-2566.	1.8	19
63	IGF-I Bioactivity Better Reflects Growth Hormone Deficiency than Total IGF-I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2248-2254.	1.8	19
64	Insulin-Like Growth Factor I: Pros and Cons of a Bioassay. <i>Hormone Research in Paediatrics</i> , 2011, 76, 106-110.	0.8	20
65	IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome. <i>Diabetes</i> , 2010, 59, 505-508.	0.3	35
66	Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 940-946.	0.4	6
67	Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. <i>Growth Hormone and IGF Research</i> , 2010, 20, 427-431.	0.5	21
68	P108 Effect of intensive insulin therapy on the somatotrophic axis in critically ill children. <i>Growth Hormone and IGF Research</i> , 2010, 20, S80.	0.5	0
69	Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. <i>European Journal of Endocrinology</i> , 2009, 160, 529-533.	1.9	110
70	Heterophilic antibodies may be a cause of falsely low total IGF1 levels. <i>European Journal of Endocrinology</i> , 2009, 161, 561-565.	1.9	19
71	Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E559-E566.	1.8	27
72	Advantages and disadvantages of GH/IGF-I combination treatment. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 157-162.	2.6	16

#	ARTICLE	IF	CITATIONS
73	Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3853-3859.	1.8	153
74	Normal Values of Circulating Insulin-Like Growth Factor-I Bioactivity in the Healthy Population: Comparison with Five Widely Used IGF-I Immunoassays. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2539-2545.	1.8	58
75	Low Circulating Insulin-Like Growth Factor I Bioactivity in Elderly Men Is Associated with Increased Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2515-2522.	1.8	78
76	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	2.0	263
77	Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E697-E704.	1.8	64
78	Intravenous Glucose Administration in Fasting Rats Has Differential Effects on Acylated and Unacylated Ghrelin in the Portal and Systemic Circulation: A Comparison between Portal and Peripheral Concentrations in Anesthetized Rats. <i>Endocrinology</i> , 2007, 148, 5278-5287.	1.4	18
79	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4598-4601.	1.8	146
80	Effects of the Renin-Angiotensin System Genes and Salt Sensitivity Genes on Blood Pressure and Atherosclerosis in the Total Population and Patients With Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1905-1912.	0.3	13
81	An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. <i>European Journal of Endocrinology</i> , 2007, 156, 83-90.	1.9	10
82	IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. <i>European Journal of Cancer</i> , 2007, 43, 1718-1722.	1.3	14
83	The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men. <i>Clinical Endocrinology</i> , 2007, 66, 808-815.	1.2	35
84	Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. <i>Molecular and Cellular Endocrinology</i> , 2006, 251, 103-111.	1.6	73
85	The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. <i>Clinical Endocrinology</i> , 2006, 64, 203-208.	1.2	5
86	An Insulin-Like Growth Factor-I Promoter Polymorphism Is Associated With Increased Mortality in Subjects With Myocardial Infarction in an Elderly Caucasian Population. <i>American Journal of Cardiology</i> , 2006, 97, 1274-1276.	0.7	18
87	Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-I. <i>European Journal of Endocrinology</i> , 2006, 155, 293-296.	1.9	18
88	Retinal Vessel Diameters and Risk of Impaired Fasting Glucose or Diabetes: The Rotterdam Study. <i>Diabetes</i> , 2006, 55, 506-510.	0.3	114
89	An IGF-I Gene Polymorphism Modifies the Risk of Diabetic Retinopathy. <i>Diabetes</i> , 2006, 55, 2387-2391.	0.3	24
90	IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , 2006, 155, 751-756.	1.9	13

#	ARTICLE	IF	CITATIONS
91	An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance. <i>European Journal of Endocrinology</i> , 2006, 154, 715-721.	1.9	10
92	The β -Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 2922-2927.	0.3	17
93	The β -bio-assay TM quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. <i>European Journal of Endocrinology</i> , 2005, 152, 217-224.	1.9	36
94	A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 289, E75-E81.	1.8	98
95	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 67-71.	1.9	42
96	A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. <i>Heart</i> , 2005, 91, 239-240.	1.2	23
97	Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6480-6489.	1.8	91
98	A Polymorphism in Type I Deiodinase Is Associated with Circulating Free Insulin-Like Growth Factor I Levels and Body Composition in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 256-263.	1.8	50
99	Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. <i>Lancet</i> , The, 2005, 365, 1644-1646.	6.3	214
100	Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1055-1060.	1.8	269
101	Circulating Free Insulin-Like Growth Factor (IGF)-I, Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4391-4396.	1.8	42
102	IGF-I and Longevity. <i>Hormone Research in Paediatrics</i> , 2004, 62, 104-109.	0.8	20
103	A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. <i>Clinical Endocrinology</i> , 2004, 61, 195-203.	1.2	74
104	Insulin-like growth factor-I gene polymorphism and risk of heart failure (the Rotterdam Study). <i>American Journal of Cardiology</i> , 2004, 94, 384-386.	0.7	37
105	The Influence of an Insulin-Like Growth Factor I Gene Promoter Polymorphism on Hip Bone Geometry and the Risk of Nonvertebral Fracture in the Elderly: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1280-1290.	3.1	64
106	There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 659-664.	1.8	8
107	Is there a role of ghrelin in preventing catabolism?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 400-403.	1.8	10
108	Administration of Acylated Ghrelin Reduces Insulin Sensitivity, Whereas the Combination of Acylated Plus Unacylated Ghrelin Strongly Improves Insulin Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5035-5042.	1.8	224

#	ARTICLE	IF	CITATIONS
109	Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. <i>American Journal of Medicine</i> , 2004, 117, 158-162.	0.6	90
110	Identification of the Bcl I polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. <i>Clinical Endocrinology</i> , 2003, 59, 585-592.	1.2	279
111	Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 588-594.	1.8	23
112	A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. <i>European Journal of Endocrinology</i> , 2003, 148, 171-175.	1.9	83
113	Endogenous Hormones and Carotid Atherosclerosis in Elderly Men. <i>American Journal of Epidemiology</i> , 2003, 157, 25-31.	1.6	221
114	Polymorphism in the Promoter Region of the Insulin-like Growth Factor I Gene Is Related to Carotid Intima-Media Thickness and Aortic Pulse Wave Velocity in Subjects With Hypertension. <i>Stroke</i> , 2003, 34, 1623-1627.	1.0	49
115	Central ghrelin production does not substantially contribute to systemic ghrelin concentrations: a study in two subjects with active acromegaly. <i>European Journal of Endocrinology</i> , 2002, 147, 195-199.	1.9	14
116	Ghrelin drives GH secretion during fasting in man. <i>European Journal of Endocrinology</i> , 2002, 146, 203-207.	1.9	135
117	A Polymorphism in the Glucocorticoid Receptor Gene, Which Decreases Sensitivity to Glucocorticoids In Vivo, Is Associated With Low Insulin and Cholesterol Levels. <i>Diabetes</i> , 2002, 51, 3128-3134.	0.3	294
118	The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. <i>European Journal of Endocrinology</i> , 2002, 146, 467-477.	1.9	63
119	Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. <i>Lancet, The</i> , 2002, 359, 1036-1037.	6.3	191
120	Insulin-like growth factor-I genotype and birthweight. <i>Lancet, The</i> , 2002, 360, 945-946.	6.3	12
121	Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency. <i>Clinical Endocrinology</i> , 2002, 56, 765-771.	1.2	29
122	Commentary: A polymorphic CA repeat in the promoter region of the insulin-like growth factor I (IGF-I) gene. <i>European Journal of Epidemiology</i> , 2002, 18, 191-194.	2.5	10
123	Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion. <i>Clinical Endocrinology</i> , 2001, 55, 461-467.	1.2	12
124	A Polymorphism in the Gene for IGF-I: Functional Properties and Risk for Type 2 Diabetes and Myocardial Infarction. <i>Diabetes</i> , 2001, 50, 637-642.	0.3	338
125	Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. <i>European Journal of Endocrinology</i> , 2001, 145, 711-716.	1.9	105
126	Control of Tumor Size and Disease Activity during Cotreatment with Octreotide and the Growth Hormone Receptor Antagonist Pegvisomant in an Acromegalic Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 478-481.	1.8	92

#	ARTICLE	IF	CITATIONS
127	Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. <i>Clinical Endocrinology</i> , 2000, 52, 1-9.	1.2	76
128	Is the measurement of free IGF-I more indicative than that of total IGF-I in the evaluation of the biological activity of the GH/IGF-I axis?. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 313-315.	1.8	32
129	Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. <i>Clinical Endocrinology</i> , 1998, 48, 471-478.	1.2	83
130	The acute effect of dexamethasone on plasma leptin concentrations and the relationships between fasting leptin, the IGF-I/IGFBP system, dehydroepiandrosterone, androstenedione and testosterone in an elderly population. <i>Clinical Endocrinology</i> , 1998, 48, 621-626.	1.2	26
131	Lack of associations between serum leptin, a polymorphism in the gene for the β -adrenergic receptor and glucose tolerance in the Dutch population.. <i>Clinical Endocrinology</i> , 1998, 49, 229-234.	1.2	26
132	The IGF-I/IGFBP system in congenital partial lipodystrophy. <i>Clinical Endocrinology</i> , 1998, 49, 465-473.	1.2	11
133	Insulin-like growth factor-I and risk of breast cancer. <i>Lancet</i> , The, 1998, 352, 490.	6.3	5
134	Insulin-like growth factor I receptors on blood cells: their relationship to circulating total and free IGF-I, IGFBP-1, IGFBP-3 and insulin levels in healthy subjects. <i>Growth Hormone and IGF Research</i> , 1998, 8, 47-54.	0.5	11
135	Serum Total IGF-I, Free IGF-I, and IGFBP-1 Levels in an Elderly Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 277-282.	1.1	223
136	Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. <i>European Journal of Endocrinology</i> , 1998, 138, 627-632.	1.9	56
137	Serum Free and Total Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein-1 and Insulin-Like Growth Factor Binding Protein-3 Levels in Healthy Elderly Individuals. <i>Gerontology</i> , 1998, 44, 277-280.	1.4	30
138	Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 (IGFBP-1), and IGFBP-3 and Their Relationships to the Presence of Diabetic Retinopathy and Glomerular Hyperfiltration in Insulin-Dependent Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2809-2815.	1.8	55
139	IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. <i>Clinical Endocrinology</i> , 1995, 43, 501-505.	1.2	42
140	Hemodynamic and Biochemical Effects of the AT 1 Receptor Antagonist Irbesartan in Hypertension. <i>Hypertension</i> , 1995, 25, 22-29.	1.3	97
141	Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.. <i>Journal of Clinical Investigation</i> , 1987, 79, 1635-1641.	3.9	365
142	Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGF1-R/INS-R antagonist OSI-906. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
143	Efficacy and safety of switching to pasireotide LAR monotherapy or in combination with pegvisomant in acromegaly patients controlled with combination therapy of somatostatin analogues and pegvisomant (PAPE study): a prospective, open-label 48 week study. <i>Endocrine Abstracts</i> , 0, , .	0.0	0